Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Bullish +75

UnitedHealth's $19.50 to $20.00 Is Not Elevance's $27+

AI-generated analysis

πŸ“ˆ Elevance Health reported third-quarter adjusted earnings tracking ahead of its prior outlook following the Wells Fargo Healthcare Conference.

πŸ’° The company reaffirmed full-year 2026 adjusted EPS guidance of at least $27.00 per share with a projected trough in Medicaid margins for that year.

πŸš€ Management forecasts at least 12% adjusted EPS growth in 2027 from the 2026 baseline supported by multiple business segments.

πŸ“Š Elevance highlighted improving cost trends across Medicare Advantage and Medicaid markets alongside stronger momentum in its Carelon health services unit.

πŸ† The stock surged nearly 6% as investors distinguished Elevance's cleaner execution record from peers like UnitedHealth Group.

πŸ” Analysts view the company's broad-based progress across segments as carrying more weight than single-line improvements seen elsewhere.

Bullish Signals
  • Third-quarter adjusted earnings are tracking ahead of the company's prior outlook, signaling strong operational performance.
  • The company reaffirmed full-year 2026 adjusted EPS guidance of at least $27.00 per share with a clear trajectory for improvement in Medicaid margins starting in 2027.
  • Management projects at least 12% adjusted EPS growth in 2027 from the 2026 baseline, supported by broad-based progress across multiple business segments.
  • Elevance demonstrated favorable cost trends in both Medicare Advantage and Medicaid markets while highlighting stronger momentum within its Carelon health services unit.
  • The stock surged nearly 6% immediately after the conference, reflecting investor confidence in the company's superior execution compared to peers.
Full Analysis
At the Wells Fargo 21st Annual Healthcare Conference, Elevance Health (ELV) CFO Marc Kaye reported that third-quarter adjusted earnings are tracking ahead of prior outlooks. The company reaffirmed its full-year 2026 adjusted earnings guidance of at least $27.00 per share and noted that 2026 is expected to be the trough year for Medicaid margins, with improvements anticipated in 2027 as rates align better with costs. Management projects at least 12% adjusted EPS growth in 2027 relative to the 2026 baseline, driven by broad-based progress across multiple business segments rather than reliance on a single line. Elevance highlighted favorable cost trends in both Medicare Advantage and Medicaid markets, alongside stronger momentum within Carelon, its health services unit, signaling a diversified recovery strategy. The market reacted positively to these updates, with ELV shares surging nearly 6% compared to UnitedHealth Group's decline. Investors view Elevance as demonstrating cleaner execution and upside surprise relative to peers, distinguishing it from competitors where guidance reaffirmations are seen merely as floors rather than catalysts for stock appreciation.